The Patent Finder

Ose Immunotherapeutics

28 patents currently held · Updated Nov 15, 2026
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jan 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 11 to 30, 2027 · next Jan 11
  • 1 fee due Feb 1, 2027
    The maintenance fee for Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer (US 11,713,356) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
  • 2 fees due Apr 1 to 8, 2027 · next Apr 1
  • 1 fee due Jul 30, 2027
    The maintenance fee for Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies (US 11,884,723) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Antibodies and Polypeptides Directed Against CD127 (US 11,926,671) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
  • 1 fee due Nov 14, 2027
    The maintenance fee for Method for Manufacturing a Stable Emulsion for Peptide Delivery (US 11,981,713) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,689,444Recombinant Monovalent Antibodies
In force
 · High confidence
In forceHigh confidence
US 8,785,138Monovalent Ligands of the Human CD28 Receptor
In force
 · High confidence
In forceHigh confidence
US 8,785,604ANTI-CD28 Humanized Antibodies
In force
 · High confidence
In forceHigh confidence
US 9,587,023Recombinant Monovalent Antibodies
In force
 · High confidence
In forceHigh confidence
US 10,364,287Anti-CD28 Humanized Antibodies
In force
 · High confidence
In forceHigh confidence
US 9,447,182Antibodies Directed Against the Alpha Chain of IL7 Receptor - Their Use for the Preparation of Drug Candidates
In force
 · High confidence
In forceHigh confidence
US 10,434,157Therapeutic multi-peptides T specific immune therapy for treatment of brain metastasis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,428,152Antibodies directed against CD127
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,440,964Method for treating a pathological condition involving the activation or proliferation of CD127 positive cells with an anti-CD127 antibody
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,371,502Antibodies directed against CD127
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 28 patents shown.
Pro members see all 28.
Pro members: see all 28 patents
Also on record, not counted in the 28: 4 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

14 pending · 7 abandoned · 12 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited